417 related articles for article (PubMed ID: 28363192)
1. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
Rawal T; Parmar R; Tyagi RK; Butani S
Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
[TBL] [Abstract][Full Text] [Related]
2. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
3. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
Rawal T; Kremer L; Halloum I; Butani S
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
[TBL] [Abstract][Full Text] [Related]
4. Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline.
Rawal T; Patel S; Butani S
Eur J Pharm Sci; 2018 Nov; 124():273-287. PubMed ID: 30176365
[TBL] [Abstract][Full Text] [Related]
5. Dry powder inhalation formulation of chitosan nanoparticles for co-administration of isoniazid and pyrazinamide.
Changsan N; Sinsuebpol C
Pharm Dev Technol; 2021 Feb; 26(2):181-192. PubMed ID: 33213232
[TBL] [Abstract][Full Text] [Related]
6. Solid Lipid Nanoparticle assemblies (SLNas) for an anti-TB inhalation treatment-A Design of Experiments approach to investigate the influence of pre-freezing conditions on the powder respirability.
Maretti E; Rustichelli C; Romagnoli M; Balducci AG; Buttini F; Sacchetti F; Leo E; Iannuccelli V
Int J Pharm; 2016 Sep; 511(1):669-679. PubMed ID: 27473279
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs.
Kaur R; Garg T; Das Gupta U; Gupta P; Rath G; Goyal AK
Artif Cells Nanomed Biotechnol; 2016; 44(1):182-7. PubMed ID: 24992699
[TBL] [Abstract][Full Text] [Related]
8. Effects of Chemical Conjugation of l-Leucine to Chitosan on Dispersibility and Controlled Release of Drug from a Nanoparticulate Dry Powder Inhaler Formulation.
Muhsin MD; George G; Beagley K; Ferro V; Wang H; Islam N
Mol Pharm; 2016 May; 13(5):1455-66. PubMed ID: 26998555
[TBL] [Abstract][Full Text] [Related]
9. Ethambutol-Loaded Solid Lipid Nanoparticles as Dry Powder Inhalable Formulation for Tuberculosis Therapy.
Nemati E; Mokhtarzadeh A; Panahi-Azar V; Mohammadi A; Hamishehkar H; Mesgari-Abbasi M; Ezzati Nazhad Dolatabadi J; de la Guardia M
AAPS PharmSciTech; 2019 Feb; 20(3):120. PubMed ID: 30796625
[TBL] [Abstract][Full Text] [Related]
10. Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach.
Patil-Gadhe A; Pokharkar V
Pulm Pharmacol Ther; 2014 Apr; 27(2):197-207. PubMed ID: 23916767
[TBL] [Abstract][Full Text] [Related]
11. Inhaled dry powder formulations for treating tuberculosis.
Das S; Tucker I; Stewart P
Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
[TBL] [Abstract][Full Text] [Related]
12. Development of Novel Octanoyl Chitosan Nanoparticles for Improved Rifampicin Pulmonary Delivery: Optimization by Factorial Design.
Petkar KC; Chavhan S; Kunda N; Saleem I; Somavarapu S; Taylor KMG; Sawant KK
AAPS PharmSciTech; 2018 May; 19(4):1758-1772. PubMed ID: 29589222
[TBL] [Abstract][Full Text] [Related]
13. Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance.
Patil-Gadhe A; Kyadarkunte A; Patole M; Pokharkar V
Eur J Pharm Biopharm; 2014 Sep; 88(1):169-77. PubMed ID: 25078860
[TBL] [Abstract][Full Text] [Related]
14. Inhalable chitosan nanoparticles as antitubercular drug carriers for an effective treatment of tuberculosis.
Garg T; Rath G; Goyal AK
Artif Cells Nanomed Biotechnol; 2016 May; 44(3):997-1001. PubMed ID: 25682840
[TBL] [Abstract][Full Text] [Related]
15. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis.
Maretti E; Rossi T; Bondi M; Croce MA; Hanuskova M; Leo E; Sacchetti F; Iannuccelli V
Int J Pharm; 2014 Feb; 462(1-2):74-82. PubMed ID: 24374224
[TBL] [Abstract][Full Text] [Related]
16. Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension.
Shahin HI; Vinjamuri BP; Mahmoud AA; Shamma RN; Mansour SM; Ammar HO; Ghorab MM; Chougule MB; Chablani L
J Control Release; 2019 May; 302():126-139. PubMed ID: 30940497
[TBL] [Abstract][Full Text] [Related]
17. Dry powder cationic lipopolymeric nanomicelle inhalation for targeted delivery of antitubercular drug to alveolar macrophage.
Vadakkan MV; Annapoorna K; Sivakumar KC; Mundayoor S; Kumar GS
Int J Nanomedicine; 2013; 8():2871-85. PubMed ID: 23990716
[TBL] [Abstract][Full Text] [Related]
18. Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery.
Sinsuebpol C; Chatchawalsaisin J; Kulvanich P
Drug Des Devel Ther; 2013; 7():861-73. PubMed ID: 24039397
[TBL] [Abstract][Full Text] [Related]
19. Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery.
Mehanna MM; Mohyeldin SM; Elgindy NA
Int J Nanomedicine; 2019; 14():9089-9112. PubMed ID: 31819421
[TBL] [Abstract][Full Text] [Related]
20. In vitro controlled release of Rifampicin through liquid-crystalline folate nanoparticles.
Parmar R; Misra R; Mohanty S
Colloids Surf B Biointerfaces; 2015 May; 129():198-205. PubMed ID: 25863713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
